Autopsy report · NCT01023269

Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder

“difficulty in the enrolment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 17 participants enrolled.
• Results were posted on the registry 6 years 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

MedtronicNeuro

Sponsor type

Industry

Conditions

Neurogenic Overactive Bladder; Urinary Incontinence; Detrusor Overactivity

Interventions

InterStim Therapy

Participants

17

Sites

8

Countries

Belgium, France, Germany, Italy, Netherlands, United Kingdom

Trials that died the same way

• Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)
  “Difficulty in enrolment” (98% match in meaning)
• Adjunctive Vitamin D in the Treatment of Non-remitted Depression
  “Difficulties with subject enrolment.” (88% match in meaning)
• Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
  “lack of enrolment” (78% match in meaning)
• Enzyme Replacement Therapy in Fabry Disease
  “Difficulties in the patient's enrolment” (77% match in meaning)
• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
  “Poor enrolment” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.